HC Wainwright Has Bearish Outlook for BCRX FY2026 Earnings

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) – Equities research analysts at HC Wainwright reduced their FY2026 earnings per share (EPS) estimates for BioCryst Pharmaceuticals in a research note issued to investors on Wednesday, October 15th. HC Wainwright analyst A. Fein now anticipates that the biotechnology company will earn $0.02 per share for the year, down from their previous forecast of $0.31. The consensus estimate for BioCryst Pharmaceuticals’ current full-year earnings is ($0.36) per share. HC Wainwright also issued estimates for BioCryst Pharmaceuticals’ FY2027 earnings at $0.34 EPS and FY2028 earnings at $0.85 EPS.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its quarterly earnings data on Monday, August 4th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.03 by $0.12. The firm had revenue of $163.35 million during the quarter, compared to analyst estimates of $149.59 million. During the same period in the prior year, the company earned ($0.06) EPS. The business’s quarterly revenue was up 49.5% compared to the same quarter last year.

BCRX has been the subject of several other research reports. Weiss Ratings restated a “sell (d-)” rating on shares of BioCryst Pharmaceuticals in a report on Wednesday, October 8th. Zacks Research upgraded shares of BioCryst Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Monday, October 6th. Evercore ISI restated an “in-line” rating and set a $8.00 price target on shares of BioCryst Pharmaceuticals in a report on Wednesday, October 1st. Bank of America raised their price target on shares of BioCryst Pharmaceuticals from $13.00 to $15.00 and gave the stock a “buy” rating in a report on Tuesday, July 1st. Finally, TD Cowen assumed coverage on shares of BioCryst Pharmaceuticals in a report on Wednesday. They set a “buy” rating and a $30.00 price target for the company. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $19.18.

BioCryst Pharmaceuticals Stock Performance

BioCryst Pharmaceuticals stock opened at $6.63 on Friday. BioCryst Pharmaceuticals has a 52-week low of $6.00 and a 52-week high of $11.31. The firm has a 50 day moving average price of $7.84 and a two-hundred day moving average price of $8.64. The firm has a market cap of $1.39 billion, a price-to-earnings ratio of -36.83, a PEG ratio of 0.78 and a beta of 1.05.

Institutional Trading of BioCryst Pharmaceuticals

Hedge funds have recently bought and sold shares of the business. Headlands Technologies LLC acquired a new stake in BioCryst Pharmaceuticals in the 1st quarter valued at $32,000. GAMMA Investing LLC grew its position in BioCryst Pharmaceuticals by 1,161.8% in the 1st quarter. GAMMA Investing LLC now owns 5,918 shares of the biotechnology company’s stock valued at $44,000 after purchasing an additional 5,449 shares during the period. Family Legacy Financial Solutions LLC acquired a new stake in BioCryst Pharmaceuticals in the 2nd quarter valued at $72,000. New Age Alpha Advisors LLC acquired a new stake in BioCryst Pharmaceuticals in the 1st quarter valued at $62,000. Finally, Allspring Global Investments Holdings LLC acquired a new stake in BioCryst Pharmaceuticals in the 1st quarter valued at $79,000. Institutional investors and hedge funds own 85.88% of the company’s stock.

Insider Activity at BioCryst Pharmaceuticals

In other news, Director Theresa Heggie sold 70,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 13th. The shares were sold at an average price of $8.51, for a total transaction of $595,700.00. Following the completion of the sale, the director owned 65,352 shares of the company’s stock, valued at $556,145.52. This trade represents a 51.72% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. 5.10% of the stock is currently owned by company insiders.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.